Bruker Corporation provided revenue guidance for the second quarter 2022. For the second quarter of 2022, outlook is for organic revenue growth in the mid- to high single digits year-over-year, subject, of course, to further COVID-related lockdowns in China or other geopolitical risks, which could negatively impact that growth.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
80.59 USD | -1.96% | +2.58% | +9.68% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.68% | 11.71B | |
+7.71% | 218B | |
+6.25% | 182B | |
+10.60% | 132B | |
+26.73% | 108B | |
-0.84% | 62.51B | |
+15.42% | 52.98B | |
-1.89% | 47.59B | |
-1.91% | 39.96B | |
+11.16% | 39.22B |
- Stock Market
- Equities
- BRKR Stock
- News Bruker Corporation
- Bruker Corporation Provides Revenue Guidance for the Second Quarter 2022